Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Squamous Non-Small Cell Lung Cancer-Pipeline Review, H1 2015

Squamous Non-Small Cell Lung Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Squamous Non-Small Cell Lung Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Squamous Non-Small Cell Lung Cancer-Pipeline Review, H1 2015', provides an overview of the Squamous Non-Small Cell Lung Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Squamous Non-Small Cell Lung Cancer Overview 9

Therapeutics Development 10

Pipeline Products for Squamous Non-Small Cell Lung Cancer-Overview 10

Pipeline Products for Squamous Non-Small Cell Lung Cancer-Comparative Analysis 11

Squamous Non-Small Cell Lung Cancer-Therapeutics under Development by Companies 12

Squamous Non-Small Cell Lung Cancer-Therapeutics under Investigation by Universities/Institutes 15

Squamous Non-Small Cell Lung Cancer-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Squamous Non-Small Cell Lung Cancer-Products under Development by Companies 19

Squamous Non-Small Cell Lung Cancer-Products under Investigation by Universities/Institutes 21

Squamous Non-Small Cell Lung Cancer-Companies Involved in Therapeutics Development 22

AbbVie Inc. 22

Advenchen Laboratories, LLC 23

Ascenta Therapeutics, Inc. 24

AstraZeneca PLC 25

Bayer AG 26

Boehringer Ingelheim GmbH 27

Bristol-Myers Squibb Company 28

Celgene Corporation 29

Eisai Co., Ltd. 30

Eli Lilly and Company 31

F. Hoffmann-La Roche Ltd. 32

Five Prime Therapeutics, Inc. 33

Genentech, Inc. 34

Johnson & Johnson 35

Novartis AG 36

Oncogenex Pharmaceuticals, Inc. 37

Ono Pharmaceutical Co., Ltd. 38

Vertex Pharmaceuticals Incorporated 39

Squamous Non-Small Cell Lung Cancer-Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Target 41

Assessment by Mechanism of Action 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

ABT-414-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

apatorsen-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

AT-406-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

AZD-8186-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

BAY-1163877-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

BMS-833923-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

BMS-906024-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

buparlisib hydrochloride-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

FP-1039-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

ipilimumab-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

JNJ-42756493-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

lenvatinib-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

lucitanib-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

lumretuzumab-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

LY-2606368-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

LY-3023414-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

necitumumab-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

nintedanib-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

nivolumab (recombinant)-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

paclitaxel albumin bound-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

pictilisib-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

Small Molecule to Inhibit TWIST1 for Non-Small Cell Lung Cancer-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

veliparib-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

VX-970-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

Squamous Non-Small Cell Lung Cancer-Recent Pipeline Updates 109

Squamous Non-Small Cell Lung Cancer-Dormant Projects 145

Squamous Non-Small Cell Lung Cancer-Discontinued Products 146

Squamous Non-Small Cell Lung Cancer-Product Development Milestones 147

Featured News & Press Releases 147

Jan 11, 2015: CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early 147

Oct 30, 2014: Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology 147

Oct 23, 2014: Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer 149

Jul 01, 2014: OncoGenex Announces Cedar Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment 150

May 14, 2014: Clovis Oncology Announces Clinical Data Of Lucitanib to Be Presented at 2014 ASCO Annual Meeting 150

Aug 13, 2013: Eli Lilly and Company's Phase III study of necitumumab meets primary endpoint 151

Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies 151

May 23, 2013: OncoGenex Pharma Announces Plans For Initiation Of Cedar Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer 152

Appendix 153

Methodology 153

Coverage 153

Secondary Research 153

Primary Research 153

Expert Panel Validation 153

Contact Us 154

Disclaimer 154

List of Tables

Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H1 2015 10

Number of Products under Development for Squamous Non-Small Cell Lung Cancer-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Squamous Non-Small Cell Lung Cancer-Pipeline by AbbVie Inc., H1 2015 22

Squamous Non-Small Cell Lung Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2015 23

Squamous Non-Small Cell Lung Cancer-Pipeline by Ascenta Therapeutics, Inc., H1 2015 24

Squamous Non-Small Cell Lung Cancer-Pipeline by AstraZeneca PLC, H1 2015 25

Squamous Non-Small Cell Lung Cancer-Pipeline by Bayer AG, H1 2015 26

Squamous Non-Small Cell Lung Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 27

Squamous Non-Small Cell Lung Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 28

Squamous Non-Small Cell Lung Cancer-Pipeline by Celgene Corporation, H1 2015 29

Squamous Non-Small Cell Lung Cancer-Pipeline by Eisai Co., Ltd., H1 2015 30

Squamous Non-Small Cell Lung Cancer-Pipeline by Eli Lilly and Company, H1 2015 31

Squamous Non-Small Cell Lung Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 32

Squamous Non-Small Cell Lung Cancer-Pipeline by Five Prime Therapeutics, Inc., H1 2015 33

Squamous Non-Small Cell Lung Cancer-Pipeline by Genentech, Inc., H1 2015 34

Squamous Non-Small Cell Lung Cancer-Pipeline by Johnson & Johnson, H1 2015 35

Squamous Non-Small Cell Lung Cancer-Pipeline by Novartis AG, H1 2015 36

Squamous Non-Small Cell Lung Cancer-Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 37

Squamous Non-Small Cell Lung Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 38

Squamous Non-Small Cell Lung Cancer-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 39

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Stage and Target, H1 2015 42

Number of Products by Stage and Mechanism of Action, H1 2015 45

Number of Products by Stage and Route of Administration, H1 2015 47

Number of Products by Stage and Molecule Type, H1 2015 49

Squamous Non-Small Cell Lung Cancer Therapeutics-Recent Pipeline Updates, H1 2015 109

Squamous Non-Small Cell Lung Cancer-Dormant Projects, H1 2015 145

Squamous Non-Small Cell Lung Cancer-Discontinued Products, H1 2015 146

List of Figures

Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H1 2015 10

Number of Products under Development for Squamous Non-Small Cell Lung Cancer-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Top 10 Targets, H1 2015 41

Number of Products by Stage and Top 10 Targets, H1 2015 41

Number of Products by Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Top 10 Routes of Administration, H1 2015 46

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 46

Number of Products by Top 10 Molecule Types, H1 2015 48

Number of Products by Stage and Top 10 Molecule Types, H1 2015 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Advenchen Laboratories, LLC

Ascenta Therapeutics, Inc.

AstraZeneca PLC

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Eisai Co., Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Genentech, Inc.

Johnson & Johnson

Novartis AG

Oncogenex Pharmaceuticals, Inc.

Ono Pharmaceutical Co., Ltd.

Vertex Pharmaceuticals Incorporated

Squamous Non-Small Cell Lung Cancer Therapeutic Products under Development, Key Players in Squamous Non-Small Cell Lung Cancer Therapeutics, Squamous Non-Small Cell Lung Cancer Pipeline Overview, Squamous Non-Small Cell Lung Cancer Pipeline, Squamous Non-Small Cell Lung Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com